过氧化物酶体增殖物激活受体β在心血管代谢性疾病中的作用

Abstract
Figure/Table
References (37)
Related Citation (12)

Download: PDF (524 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract The prevalence and mortality rate of cardiometabolic diseases continue to rise, which seriously threaten human’s health. Peroxisome proliferator activated receptor β (PPARβ) and its ligands has the role of anti-inflammatory, anti-oxidative stress and improving the metabolism of glucose and lipid, that is to show the role of protecting cardiovascular and adjusting metabolism. In this paper, PPARβ and its ligands were reviewed in the aspects of lowering blood pressure, anti-atherosclerosis, improving endothelial function, reversing cardiomyocyte hypertrophy, improving insulin sensitivity and preventing obesity, to provide a reference for colleagues to further dig the prevention and treatment value of PPARβ on cardiovascular disease.

Key words： Peroxisome proliferator activated receptorβ Cardiometabolic diseases Inflammation Oxidative stress

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIU Sen1.2 WANG Dan1.2 CAI Guocai1.2 WANG Peijian1.2

Cite this article:

LIU Sen1.2 WANG Dan1.2 CAI Guocai1.2 WANG Peijian1.2. Roles of peroxisome proliferator activated receptor β in cardiometabolic diseases[J]. 中国医药导报, 2018, 15(5): 32-36.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2018/V15/I5/32

[1] WHO. On World Heart Day WHO calls for accelerated action to prevent the world’s leading global killer [EB/OL].（2017-09-22）[2017-11-14]. http：//www.who.int/cardiovascular_diseases/en/.
[2] 陈伟伟，高润霖，刘力生，等.《中国心血管病报告2016》概要[J].中国循环杂志，2017，32（6）：521-530.
[3] Wang L，Gao P，Zhang M，et al. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013 [J]. JAMA，2017，317（24）：2515-2523.
[4] 何宇纳，赵文华，赵丽云，等.中国2010-2012年成年人代谢综合征流行特征[J].中华流行病学杂志，2017，38（2）：212-215.
[5] Gourdin M，Keum YY，Pham XY. Chronic peroxisome proliferator-activated receptorβ/δagonist GW0742 prevents hypertension， vascular inflammatory and oxidative status， and endothelial dysfunction in diet-induced obesity [J]. J Hypertens，2015，33（9）：1831-1844.
[6] Maccallini C，Mollica A，Amoroso R. The positive regulation of eNOS signaling by PPAR agonists in cardiovascular diseases [J]. Am J Cardiovasc Drugs，2017，17（4）：273-281.
[7] Cheang WS，Tian X，Wong W，et al. The peroxisome proliferator-activated receptors in cardiovascular diseases：experimental benefits and clinical challenges [J]. Br J Pharmacol，2015，172（23）：5512-5522.
[8] Peters JM，Foreman JE，Gonzalez FJ. Dissecting the role of peroxisome proliferator-activated receptor-β/δ （PPARβ/δ） in colon， breast， and lung carcinogenesis [J]. Cancer Metastasis Rev，2011，30（3-4）：619-640.
[9] Michalik L，Wahli W. Peroxisome proliferator-activated receptors（PPARs）in skin health，repair and disease [J]. Biochim Biophys Acta，2007，1771（8）：991-998.
[10] Bility MT，Devlindurante MK，Blazanin N，et al. Ligand activation of peroxisome proliferator-activated receptor β/δ（PPARβ/δ） inhibits chemically induced skin tumorigenesis [J]. Carcinogenesis，2008，29（12）：2406-2414.
[11] Paterniti I，Impellizzeri D，Crupi R，et al. Molecular evidence for the involvement of PPAR-δ and PPAR-γ in anti-inflammatory and neuroprotective activities of palmitoylethanolamide after spinal cord trauma [J]. J Neuroinflammation，2013，10（1）：787.
[12] Toral M，Romero M，Perez-vizcaino F，et al. Antihypertensive effects of peroxisome proliferator-activated receptor-beta/delta activation [J]. Am J Physiol Heart Circ Physiol，2017，312（2）：189-200.
[13] Zarzuelo MJ，Jiménez R，Galindo P，et al. Antihypertensive effects of peroxisome proliferator-activated receptor-beta activation in spontaneously hypertensive rats [J]. Hypertension，2011，58（4）：733-743.
[14] Zarzuelo MJ，Gómezguzmán M，Jiménez R，et al. Effects of peroxisome proliferator-activated receptor-beta activation in endothelin-dependent hypertension [J]. Cardiovasc Res，2013，99（4）：622-631.
[15] Romero M，Jimenez R，Toral M，et al. Vascular and Central activation of peroxisome proliferator-activated receptor-beta attenuates angiotensin II-Induced hypertension：Role of RGS-5 [J]. J Pharmacol Exp Ther，2016， 358（1）：151-163.
[16] Yao PL，Morales JL，Gonzalez FJ，et al. Peroxisome proliferator-activated receptor-beta/delta modulates mast cell phenotype [J]. Immunology，2017，150（4）：456-467.
[17] 秦春焕，李红莉.PPARβ及其配体在RAW264.7泡沫细胞模型中的作用[J].中国分子心脏病学杂志，2014，14（6）：1139-1143.
[18] Li AC，Binder CJ，Gutierrez A，et al. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha，beta/delta，and gamma [J]. J Clin Invest，2004，114（11）：1564-1576.
[19] Jiménez R，Sánchez M，Zarzuelo MJ，et al. Endothelium-dependent vasodilator effects of peroxisome proliferator-activated receptor beta agonists via the phosphatidyl-inositol-3 kinase-Akt pathway [J]. J Pharmacol Exp Ther，2010，332（2）：554-561.
[20] Quintela A M，Jiménez R，Piqueras L，et al. PPARbeta activation restores the high glucose-induced impairment of insulin signalling in endothelial cells [J]. Br J Pharmacol，2014，171（12）：3089-3102.
[21] Quintela AM，Jiménez R，Gómez-Guzmán M，et al. Activation of peroxisome proliferator-activated receptor-beta/-delta（PPARbeta/delta）prevents endothelial dysfunction in type 1 diabetic rats [J]. Free Radic Biol Med，2012，53（4）：730-741.
[22] Toral M，Romero M，Jiménez R，et al. Carnitine palmitoyltransferase-1 up-regulation by PPAR-beta/delta prevents lipid-induced endothelial dysfunction [J]. Clin Sci（Lond），2015，129（9）：823-837.
[23] Morales-Cano D，Moreno L，Barreira B，et al. Activation of PPARbeta/delta prevents hyperglycaemia-induced impairment of Kv7 channels and cAMP-mediated relaxation in rat coronary arteries [J]. Clin Sci（Lond），2016， 130（20）：1823-1836.
[24] Romero M，Toral M，Robles-Vera I，et al. Activation of peroxisome proliferator activator receptor beta/delta improves endothelial dysfunction and protects kidney in murine lupus [J]. Hypertension，2017，69（4）：641-650.
[25] Wawrzyniak M，Pich C，Gross B，et al. Endothelial， but not smooth muscle，peroxisome proliferator-activated receptor beta/delta regulates vascular permeability and anaphylaxis [J]. J Allergy Clin Immunol，2015，135（6）：1625-1635.
[26] Eleftheria B，Anikó G，Renáta G，et al. Activation of PPARβ/δ protects cardiac myocytes from oxidative stress-induced apoptosis by suppressing generation of reactive oxygen/nitrogen species and expression of matrix metalloproteinases [J]. Pharmacol Res，2015，95（8）：102-110.
[27] Chang WT，Cheng JT，Chen ZC. Telmisartan improves cardiac fibrosis in diabetes through peroxisome proliferator activated receptor delta（PPARdelta）：from bedside to bench [J]. Cardiovasc Diabetol，2016，15（1）：113.
[28] Zhang Y，Liao P，Zhu M，et al. Baicalin attenuates cardiac dysfunction and myocardial remodeling in a chronic pressure-overload mice model [J]. Cell Physiol Biochem，2017，41（3）：849-864.
[29] Daoudi M，Hennuyer N，Borland MG，et al. PPARbeta/delta activation induces enteroendocrine L cell GLP-1 production [J]. Gastroenterology，2011，140（5）：1564-1574.
[30] Yang Y，Tong Y，Gong M，et al. Activation of PPARbeta/delta protects pancreatic beta cells from palmitate-induced apoptosis by upregulating the expression of GLP-1 receptor [J]. Cell Signal，2014，26（2）：268-278.
[31] Iglesias J，Barg S，Vallois D，et al. PPARbeta/delta affects pancreatic beta cell mass and insulin secretion in mice [J]. J Clin Invest，2012，122（11）：4105-4117.
[32] Vázquez-Carrera M. Unraveling the effects of PPARbeta/delta on insulin resistance and cardiovascular disease [J]. Trends Endocrinol Metab，2016，27（5）：319-334.
[33] Serrano-Marco L，Rodríguez-Calvo R，El Kochairi I，et al. Activation of peroxisome proliferator-activated receptor-beta/-delta （PPAR-beta/-delta） ameliorates insulin signaling and reduces SOCS3 levels by inhibiting STAT3 in interleukin-6-stimulated adipocytes [J]. Diabetes，2011， 60（7）：1990-1999.
[34] Salvadó L，Barroso E，Gómezfoix AM，et al. PPARbeta/delta prevents endoplasmic reticulum stress-associated inflammation and insulin resistance in skeletal muscle cells through an AMPK-dependent mechanism [J]. Diabetologia，2014，57（10）：2126-2135.
[35] Penna-de-Carvalho A，Graus-Nunes F，Rabelo-Andrade J，et al. Enhanced pan-peroxisome proliferator-activated receptor gene and protein expression in adipose tissue of diet-induced obese mice treated with telmisartan [J]. Exp Physiol，2014，99（12）：1663-1678.
[36] Ming GF，Li X ，Yin JY，et al. JAZF1 regulates visfatin expression in adipocytes via PPARalpha and PPARbeta/delta signaling [J]. Metabolism，2014，63（8）：1012-1021.
[37] Derosa G，Sahebkar A，Maffioli P. The role of various peroxisome proliferator-activated receptors and their ligands in clinical practice [J]. J Cell Physiol，2017，233（1）：153-161.